This Quarterly Report on Form 10-Q contains "forward-looking statements" that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The statements contained herein that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are often identified by the use of words such as, but not limited to, "anticipates," "believes," "can," "continues," "could," "estimates," "expects," "intends," "may," "will be," "plans," "projects," "seeks," "should," "targets," "will," "would," and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled "Risk Factors" included in our Annual Report on Form 10-K for the year endedDecember 31, 2021 filed onMarch 31, 2022 , as subsequently amended onMay 2, 2022 (the "2021 Annual Report"), our Quarterly Reports on Form 10-Q for the three months endedMarch 31, 2022 andJune 30, 2022 , and this Quarterly Report on Form 10-Q and any future reports we file with theSecurities and Exchange Commission ("SEC"). The forward-looking statements set forth herein speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. All references in this Quarterly Report on Form 10-Q to "we," "us" and "our" refer toXWELL, Inc. (prior toOctober 25, 2022 andJanuary 5, 2018 , known as "XpresSpa Group, Inc. " and "FORM Holdings Corp "), aDelaware corporation, and its consolidated subsidiaries unless the context requires otherwise.
Overview
OnOctober 25, 2022 , we changed our name toXWELL, Inc. ("XWELL" or the "Company") fromXpresSpa Group, Inc. Our common stock, par value$0.01 per share, which had previously been listed under the trading symbol "XSPA" on the Nasdaq Capital Market, now trades under the trading symbol "XWEL" since the opening of the trading market onOctober 25, 2022 . Rebranding toXWELL, Inc. aligned our corporate strategy to build a pure-play health and wellness services company, both in the airport and off-airport marketplaces. XWELL, is a leading global travel health and wellness services holding company. XWELL currently has four reportable operating segments: XpresSpa®, XpresTest®, Treat™ and HyperPointe. XWELL's subsidiary,XpresSpa Holdings, LLC ("XpresSpa") has been a global airport retailer of spa services through itsXpresSpa spa locations, offering travelers premium spa services, including massage, nail and skin care, as well as spa and travel products. XWELL's subsidiary,XpresSpa Holdings, LLC ("XpresSpa") has been a global airport retailer of spa services through itsXpresSpa spa locations, offering travelers premium spa services, including massage, nail and skin care, as well as spa and travel products. Most ofXpresSpa spa locations were closed betweenMarch 2020 andSeptember 2021 , largely due to the airport traffic remaining at insufficient levels to support operations at a unit level. During the period betweenMarch 2020 andSeptember 2021 , when we were unable to reopen our spa locations for normal operations, in partnership with certain COVID-19 testing partners, we successfully launched ourXpresCheck Wellness Centers through ourXpresTest, Inc. subsidiary ("XpresTest"), offering testing services, also in airports. XpresTest offers COVID-19 and other medical diagnostic testing services to the traveling public, as well as airline, airport and concessionaire employees, andTSA andU.S. Customs and Border Protection agents. XpresTest has entered into MSAs with professional medical services companies or professional limited liability companies ("PLLCs") that provide health care services to patients. The PLLCs pay XpresTest a monthly fee to operate in theXpresCheck Wellness Centers . Under the terms of MSAs, we provide office space, equipment, supplies, non-licensed staff, and management services in return for a management fee. EffectiveJuly 1, 2021 , we determined that the PLLCs are VIEs due to their equity holders having insufficient capital at risk, and the Company having a variable interest in and being a primary beneficiary of these PLLCs. 30 Table of Contents
Furthermore, XWELL continues to develop Treat, a travel health and wellness brand that is positioned for a post-pandemic world. Treat's on-site centers (currently located inJFK International Airport ,Phoenix Sky Harbor International Airport andSalt Lake City International Airport) provide access to health and wellness services for travelers. Our teams provide travel-related diagnostic testing for virus, cold, flu and other illnesses as well as hydration therapy, IV drips, and vitamin injections. Travelers can purchase time blocks to use our wellness rooms to engage in interactive services like self-guided yoga, meditation and low impact weight exercises or to relax and unplug from the hectic pace of the airport and renew themselves before or after their trip. The integration and expansion of services and products, both domestically and internationally, is part of our objective to grow airport business. Treat offers a website (www.treat.com) and mobile app to complement the offering with relevant health and wellness content designed to help people on the go with information that could impact their travel. The platform provides travelers access to a comprehensive online marketplace of services including global illness tracker tools such as the COVID-19 Requirements Map, on-demand chat care by licensed providers, a health wallet to store personal and family health records (including COVID-19 testing results), and a scheduler to arrange for direct care at one of our on-site locations. The information on the Treat website is not incorporated by reference into this Quarterly Report on Form 10-Q and does not constitute a part of this Form 10-Q.
Our HyperPointe segment, which we acquired in
range of service and support options for our customers, including technical
support services and advanced services.
Although we recognize four segments of business, our strategy for the future, is to create and leverage a fully integrated set of products and services that are both profitable and scalable across our portfolio of brands. Additionally, we will expand our retail strategy, not only adding more products for sale but aligning those products more efficiently to our service offerings. For example, adding fortified water and hydration packets to the delivery of an onsite hydration IV or adding muscle relaxation patches to a neck or back massage to continue treatment after the delivery of the service. The integration and expansion of services and products, both domestically and internationally, is part of our objective to grow airport business. We also plan to build our capability for delivering health and wellness services outside the airport. We believe operating outside of the airport complements our offering and allows us to scale growth faster.
These strategic imperatives will be accomplished through development of an
infrastructure specifically focused on enabling scalable and efficient growth.
While management has used all currently available information in assessing our business prospects, the ultimate impact of the COVID-19 pandemic on ourXpresCheck Wellness Centers and on our results of operations, financial condition and cash flows remains uncertain and could have a material effect
on our business. Recent DevelopmentsXpresSpa There are currently twenty operatingXpresSpa domestic locations, and we expect to re-open two additional domestic locations in 2022. During 2022, we sold our two franchise locations in Austin-Bergstrom International Airport A majority of the domesticXpresSpa locations are operating approximately eight hours per day during the busiest hours (compared to up to sixteen hours per day pre-pandemic). Additionally,XpresSpa implemented a price increase inmid-October 2021 in its efforts to return to profitability. As we continue to monitor fluctuating airport volumes, we will continue to review our operating hours to optimize revenue opportunity. During the fourth quarter of 2021, we began testing several new services to take advantage of a growing interest in non-traditional spa services and expansion of our retail offering to align more closely with the services we provide. We are evaluating the success of these new initiatives at each airport on an on-going basis and will incorporate changes to our approach as more of the portfolio
is
reactivated.
31
Table of Contents
There are also eight international locations operating, including three XpresSpa
locations in Dubai International Airport in the United Arab Emirates , three
XpresSpa locations in Schiphol Amsterdam Airport in the Netherlands and two
XpresSpa locations in Istanbul Airport in Turkey . The Company had signed for 5
locations at Istanbul Airport in Turkey of which 3 of them opened after
September 30, 2022 :, and we expect to open an additional two locations before
the end of 2022.
We have received rent concessions from landlords on a majority of our leases,
allowing for the relief of minimum guaranteed payments in exchange for
percentage-of-revenue rent or providing relief from rent through payment
deferrals. The periods of relief from these payments, which began in March 2020 ,
ranged from three to twenty-eight months enabling us to receive minimum
guaranteed payment concessions of approximately $431 and $1,568 in the nine
months ended September 30, 2022 and 2021, respectively.
XpresTest’s business has management services agreements with state licensed
physicians and nurse practitioners, under which we administer COVID-19 testing
options, including a Polymerase Chain Reaction (PCR) test and a rapid PCR test.
As of the date of this report, there are eight operating XpresCheck locations operating in eight airports, including anXpresCheck Wellness Center inOrlando International Airport , pre-security, in the South Walk area of theMain Terminal , which opened inMarch 2022 . During 2022, as countries continued to relax their testing requirements resulting in rapid decline of testing volumes at our XpresCheck locations, we closed or consolidated our five non performingXpresCheck Wellness Centers and twoXpresCheck Wellness Centers were assimilated into the Treat Segment. During 2021, XpresTest initiated a$2,001 , eight-week pilot program with theCenters for Disease Control and Prevention (CDC ) in collaboration with Concentric by Ginkgo Bioworks (NYSE: DNA). Under this program, XpresTest is conducting biosurveillance monitoring at four majorU.S. airports (JFK International Airport ,Newark Liberty International Airport ,San Francisco International Airport , andHartsfield-Jackson Atlanta International Airport ) aimed at identifying existing and new SARS-CoV-2 variants. OnJanuary 31, 2022 , we announced the extension of the program, bringing the total contract to$5,534 . Approximately$4,166 and$1,368 of the full$5,534 amount was recognized during the first half of 2022 and the fourth quarter of 2021, respectively. During the third quarter of 2022, XpresTest, in partnership with Ginkgo Bioworks in continuation of their support to theCDC 's traveler-based SARS-CoV-2 genomic surveillance program were awarded a new contract. The partnership is expected to support public health and biosecurity services totaling approximately$16,000 , with an overall potential to exceed$61,000 based onCDC program options and public health priorities. As COVID-19 sub variants and other biological threats continue to emerge, the partners plan to expand the program footprint and incorporate innovative modalities and offerings, such as monitoring of wastewater from aircraft lavatories. The current contract with Ginkgo Bioworks related to the above partnership contains fixed pricing for which we are entitled to$6,761 for the sample collection (passenger and aircraft wastewater) and$570 for the traveler enrollment initiatives, which represents the amount of consideration that we are entitled. We recognizes revenue over time for both sample collection performance obligations, using the input method based on time elapsed to measure progress towards satisfying each of the performance obligations. We recognize revenue ratably (straight line basis) over the term of the contract (one year). We will recognize revenue over time for the traveler enrollment initiative performance obligation based on the amount for which we have the right to invoice. We recorded$916 in revenue during the quarter endedSeptember 30, 2022 .
Treat
Treat is our new travel, health and wellness brand transforming the way we
access care through a suite of health and wellness services supported by an
integrated digital platform and a relevant retail offering to the traveling
public.
32
Table of Contents
Treat's on-site centers (currently located in JFK International Airport , Phoenix
Sky Harbor International Airport and Salt Lake City International Airport)
provide access to health and wellness services for travelers. Our teams provide
travel-related diagnostic testing for virus, cold, flu and other illnesses as
well as hydration therapy, IV drips, and vitamin injections. Travelers can
purchase time blocks to use our wellness rooms to engage in interactive services
like self-guided yoga, meditation and low impact weight exercises or to relax
and unplug from the hectic pace of the airport and renew themselves before
or after their trip. HyperPointe Acquisition InJanuary 2022 , we acquired gcgConnect, LLC d/b/a HyperPointe. HyperPointe is a leading digital healthcare and data analytics relationship marketing agency servicing the global healthcare and pharmaceutical industry. HyperPointe has significant experience in patient and healthcare professional marketing and deep technological experience with CXM (customer experience management) and data analytics. SinceJune 2020 , HyperPointe's management team and suite of services and technology have been used to develop and deploy the technological infrastructure needed to scale the growth of our XpresTest business HyperPointe's experience in this space continues to serve the XpresTest business and we expect it will play a critical role in the expansion of our on-going biosurveillance collaboration with theCDC . The purchase price in the transaction consisted of$7,121 in cash and$906 in common stock, offset by the settlement of intercompany accounts payable of$770 . as well as potential additional earn-out payments of up to$7,500 over a three-year timeframe based upon future performance; these earn-out payments may be satisfied in cash or common stock or a combination thereof subject to various terms and conditions. HyperPointe currently operates as a segment within XWELL.Ezra Ernst , who was the chief executive officer of HyperPointe before our acquisition, continues to serve as the chief executive officer of HyperPointe, as well as the chief executive officer of XpresTest, reporting toScott Milford , XWELL CEO.
Results of Operations
Revenue
We recognize revenue from the sale ofXpresSpa services when they are rendered at our stores and from the sale of products at the time goods are purchased at our stores or online (usually by credit card), net of discounts and applicable sales taxes. We have entered into managed services agreements with professional medical services companies that provide healthcare services to patients in our XpresCheck andTreat Wellness Centers . The medical services companies will pay XpresTest and Treat, a monthly management fee to operate in the XpresCheck andTreat Wellness Centers . Our HyperPointe segment provides broad range of service and support options for our customers, including technical support services and advanced services. Technical support services represent the majority of these offerings which are distinct performance obligations that are satisfied over time with revenue recognized ratably over the contract term.
Cost of sales
Cost of sales for ourXpresSpa segment consists of store-level costs. Store-level costs include all costs that are directly attributable to the store operations, primarily payroll and related benefit costs for store personnel, occupancy costs and cost of products sold. Cost of sales of our XpresTest and Treat segments include costs related to the XpresCheck and Treat Medical Office business, and consists of expenses directly attributable to the clinic operations under the terms of the MSAs, primarily payroll and related benefit costs for personnel, occupancy costs and cost of supplies used to administer the diagnostic COVID-19 tests and a suite of health and wellness services 33 Table of Contents General and administrative
General and administrative expenses include management and administrative
personnel, overhead and occupancy costs, insurance and various professional
fees, as well as stock-based compensation for directors, management and
administrative personnel.
Three months ended
Revenue
Three months ended September 30,
2022 2021 Inc/(Dec)
Total revenue
The decrease in revenue of$16,031 or 60%, was primarily due to reduction in patient service revenue triggered by the rapid decline of the XpresTest segment as countries continued to relax their testing requirements, testing volumes at our XpresCheck locations decreased as we progressed through 2022. We saw an increase in revenue associated with theXpresSpa locations that opened during and after the third quarter of 2021.
Cost of sales
Three months ended September 30,
2022 2021 Inc/(Dec)
Cost of sales
The decrease in cost of sales of$4,323 or 32%, was primarily due to the decrease in revenues resulting in decreased costs to operate the decreased volume at XpresCheck locations. There were some related costs of sales triggered by the reopening of certainXpresSpa locations that were temporarily closed during the second quarter of 2021. We had twenty open Spa locations as ofSeptember 30, 2022 , and two open Spa locations as ofSeptember 30, 2021 . The largest component in the cost of sales are costs of testing kits and labor costs at the location-level. Cost of sales also includes rent and related occupancy costs, which can primarily include rent based on percentage of sales, as well as other product costs directly associated with the procurement of retail inventory, and other operating costs.
Depreciation and amortization
Three months ended September 30,
2022 2021
Inc/(Dec)
Depreciation and amortization
The increase in depreciation and amortization of approximately 84% was primarily
due to depreciation and amortization related to the XpresCheck and
Wellness Centers
34
Table of Contents
Impairment/loss on disposal of assets
Three months ended September
30,
2022 2021
Inc/(Dec)
Impairment/Loss on disposal of assets
1,040
Impairment/loss on disposal of assets primarily pertain to closure of XpresCheck
Locations triggered by the rapid decline in testing volumes at our XpresCheck
locations as countries continue to relax their testing requirements.
General and administrative
Three months ended September 30,
2022 2021 Inc/(Dec)
General and administrative $ 6,447 $ 5,196 $ 1,251
The increase of approximately 24% was primarily due to functional costs
associated with the operations of more XpresCheck and
Other non-operating expense, net
Three months ended September 30,
2022 2021
Inc/(Dec)
Other non-operating expense, net
245
The following is a summary of the transactions included in other non-operating
expense, net for the three months ended
Three months ended September 30,
2022 2021
Loss on equity investments $ (98) $ (302)
Bank fees and financing charges (38) (62)
Other - (17)
Total $ (136) $ (381)
Interest income, net
Three months ended September 30,
2022 2021 Inc/(Dec)
Interest income, net $ 114 $ 6 $ 108
Interest income, net increased as a result of increased interest rates and
elimination of interest expense since the beginning of
35
Table of Contents
Nine months endedSeptember 30, 2022 compared to the Nine months endedSeptember 30, 2021 Revenue Nine months ended September 30, 2022 2021 Inc/(Dec) Total revenue$ 48,381 $ 44,371 $ 4,010 The increase in revenue of$4,010 or 9%, was primarily due to patient service revenue triggered by the rapid growth of the XpresTest segment with the addition of more locations betweenOctober 1, 2021 andJune 30, 2022 . The Company also saw an increase in revenue associated with theXpresSpa locations that opened afterOctober 1, 2021 . Cost of sales Nine months ended September 30, 2022 2021 Inc/(Dec) Cost of sales$ 36,743 $ 25,522 $ 11,221
The increase in cost of sales of$11,221 or 44%, was due to the increase in revenues resulting in increased costs to operate the increased number of XpresCheck locations and the reopening of certainXpresSpa locations that were temporarily closed during the second quarter of 2021. We had 20 open Spa locations as ofSeptember 30, 2022 , and two open Spa locations as ofSeptember 30, 2021 . The largest component in the cost of sales are costs of testing kits and labor costs at the location-level. Cost of sales also includes rent and related occupancy costs, which can primarily include rent based on percentage of sales, as well as other product costs directly associated with the procurement of retail inventory, and other operating costs.
Depreciation and amortization
Nine months ended September 30,
2022 2021 Inc/(Dec)
Depreciation and amortization
The increase in depreciation and amortization of approximately 70% was primarily due to depreciation and amortization related to XpresCheck andTreat Wellness Centers afterSeptember 30, 2021 .
Impairment/loss on disposal of assets
Nine months ended September
30,
2022 2021
Inc/(Dec)
Impairment/Loss on disposal of assets
Impairment/loss on disposal of assets primarily pertain to closure of XpresCheck
Locations triggered by the rapid decline in testing volumes at our XpresCheck
locations as countries continue to relax their testing requirements.
36
Table of Contents
General and administrative
Nine months ended September 30,
2022 2021 Inc/(Dec)
General and administrative $ 24,193 $ 14,350 $ 9,843
The increase of approximately 69% was primarily due to functional costs
associated with the operations of XpresCheck and
Other non-operating expense, net
Nine months ended September 30,
2022 2021
Inc/(Dec)
Other non-operating expense, net
180
The following is a summary of the transactions included in other non-operating
expense, net for the nine months ended
Nine months ended September 30,
2022 2021
Loss on equity investments $ (528) $ (716)
Bank fees and financing charges
(122) (97)
Other - (17)
Total $ (650) $ (830)
Interest income, net
Nine months ended September 30,
2022 2021 Inc/(Dec)
Interest income, net $ 159 $ 31 $ 128
Interest income, net increased as a result of increased interest rates and
elimination of interest expense since the beginning of
Liquidity and Capital Resources
As ofSeptember 30, 2022 , we had cash and cash equivalents, excluding restricted cash, of$49,429 , total current assets of$55,181 , total current liabilities of$10,984 and positive working capital of$44,197 , compared to a positive working capital of$89,152 as ofDecember 31, 2021 . We have performed an assessment of our ability to continue as a going concern. As of the date of the report, we believes that our Company has sufficient liquidity to fund operations for the next twelve months. Our liquidity projections and actual performance through issuance relies heavily on the success and profitability of our re-openedXpresSpa locations, and tailored service offerings. In addition, our future liquidity relies on the market acceptance to our new travel, health and wellness brand, Treat, which has generated a net loss of$1,290 and$4,049 , for the three and nine months endedSeptember 30, 2022 , respectively. Furthermore, because we rely heavily on international and domestic airplane travel, any such decrease in demand for travel could have a negative impact on the Company's operations
and
liquidity.
37
Table of Contents
On August 31, 2021 , our board of directors initially authorized a stock
repurchase program that permitted the purchase and repurchase of up to 15
million shares of our common stock through September 15, 2022 . In May 2022 , the
Board increased the share repurchase program by an additional 10 million shares
and extended its effectiveness through September 15, 2023 . Under the new stock
repurchase program, management has discretion in determining the conditions
under which shares may be purchased from time to time. The program does not
require us to repurchase any specific number of shares, and may be modified,
suspended or terminated at any time without prior notice. Under the program, we
purchased and retired 19,526,706 shares for $23,789 during the nine months ended
September 30, 2022 .
While we have addressed our working capital deficiency and long-term debt, and
continue to focus on our overall operating profitability, we expect to incur net
losses in the foreseeable future. In addition, the ongoing impact of the
COVID-19 pandemic on our business going forward remains uncertain at this time
and may result in additional material adverse impacts on our liquidity position
and access to capital.
Critical Accounting Estimates
These condensed consolidated financial statements should be read in conjunction
with the audited consolidated financial statements included in our Annual Report
on Form 10-K for the year ended December 31, 2021 , as amended, filed with the
SEC which includes a description of our critical accounting estimates that
involve subjective and complex judgments that could potentially affect reported
results. There have been no material changes to our critical accounting
estimates as to the methodologies or assumptions we apply under them. We
continue to monitor such methodologies and assumptions.
Adjusted EBITDA
Adjusted EBITDA is a supplemental measure of financial performance that is not required by or presented in accordance with GAAP but is a measurement used by management to assess the trends in our business. In evaluating our performance as measured by Adjusted EBITDA, we recognize and consider the limitations of this measurement.
We define Adjusted EBITDA as earnings before interest, taxes, depreciation and
amortization expense, non-cash charges, and stock-based compensation expense.
We consider Adjusted EBITDA to be an important indicator for the performance of our operating business, but it is not a measure of performance or liquidity calculated in accordance with GAAP. We have included this non-GAAP financial measure because management utilizes this information for assessing our performance and liquidity, and as an indicator of our ability to make capital expenditures and finance working capital requirements. We believe that Adjusted EBITDA is a measurement that is commonly used by analysts and some investors in evaluating the performance and liquidity of growth companies such as ours. In particular, we believe that it is useful for analysts and investors to understand that Adjusted EBITDA excludes certain transactions not related to our core cash operating activities, which are primarily related to ourXpresCheck Wellness Centers . We believe that excluding these transactions allows investors to meaningfully analyze the performance of our core cash operations. Adjusted EBITDA should not be considered in isolation or as an alternative to cash flow from operating activities or as an alternative to operating income or as an indicator of operating performance or any other measure of performance derived in accordance with GAAP. Adjusted EBITDA does not reflect our obligations for the payment of income taxes, interest expense, or other obligations such as capital expenditures. 38
Table of Contents
A reconciliation of operating income (loss) from operations presented in
accordance with GAAP for the three and nine month periods ended
2022
Q3 2022 Results of Operations and Adjusted EBITDA
(Amounts in thousands)
Three months ended September 30, Nine months ended September 30,
Revenue: 2022 2021 2022 2021
Managed services fees $ - $ - $ - $ 16,843
Patient service revenue 4,607 25,351 31,728 25,351
Services 4,924 1,158 13,488 1,761
Products 542 258 1,308 402
Hyperpointe Services 659 - 1,853 -
Other 4 - 4 14
Total revenue 10,736 26,767 48,381 44,371
Cost of sales
Labor 5,222 4,277 16,161 7,419
Occupancy 1,082 587 3,412 1,511
Product and other operating
costs 3,035 8,798 17,170 16,592
Total cost of sales 9,339 13,662 36,743 25,522
Depreciation and
amortization 1,564 852 4,329 2,542
Impairment of long-lived
assets 677 - 677 -
Loss on disposal of assets,
net 325 - 273 22
Impairment of operating
lease right-of-use assets 38 - 38 -
General and administrative 6,447 5,196 24,193 14,350
Total operating expense 18,390 19,710 66,253 42,436
(Loss) income from
operations (7,654) 7,057 (17,872) 1,935
Interest income, net 114 6 159 31
Other non-operating expense,
net (136) (381) (650) (830)
(Loss) income before income
taxes (7,676) 6,682 (18,363) 1,136
Income tax expense (3) (87) (5) (79)
Net (loss) income (7,679) 6,595 (18,368) 1,057
Net loss (income)
attributable to
noncontrolling interests 500 (998) (1,012) (983)
Net (loss) income
attributable to common
shareholders $ (7,179) $ 5,597 $ (19,380) $ 74
(Loss) income from
operations $ (7,654) $ 7,057 $ (17,872) $ 1,935
Add back:
Depreciation and
amortization 1,564 852 4,329 2,542
Impairment of long-lived
assets 677 - 677 -
Loss on disposal of assets,
net 325 - 273 22
Impairment of operating
lease right-of-use assets 38 - 38 -
Stock-based compensation
expense 483 790 3,346 2,123
Adjusted EBITDA $ (4,567) $ 8,699 $ (9,209) $ 6,622
© Edgar Online, source
link